BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
| Revenue (TTM) | $2.81B |
| Gross Profit (TTM) | $2.21B |
| EBITDA | $-1.19B |
| Operating Margin | -577.00% |
| Return on Equity | -6.66% |
| Return on Assets | -4.18% |
| Revenue/Share (TTM) | $11.45 |
| Book Value | $84.56 |
| Price-to-Book | 1.03 |
| Price-to-Sales (TTM) | 8.50 |
| EV/Revenue | 2.611 |
| EV/EBITDA | 32.70 |
| Quarterly Earnings Growth (YoY) | -43.20% |
| Quarterly Revenue Growth (YoY) | -35.40% |
| Shares Outstanding | $252.88M |
| Float | $110.10M |
| % Insiders | 57.13% |
| % Institutions | 20.33% |
Volatility is currently expanding
BioNTech has held confidential talks with potential buyers about the German sites that the COVID‑19 vaccine maker plans to close, which has now grown to four locations, the Handelsblatt newspaper reported on Friday.
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel told the German business daily Handelsblatt on Wednesday.
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment option Continued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart.
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was represented at the virtual assembly.
BioNTech NASDAQ: BNTX used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network.
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027.
A German government spokesperson said on Wednesday that the loss of BioNTech vaccine production in the country can be offset by other companies.
